About 31 results found for searched term "p38 MAPK" (0.085 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M14177 | p38-α MAPK-IN-1 | p38 MAPK |
| p38-α MAPK-IN-1 is an inhibitor of MAPK14 (p38-α), with IC50 of 2300 nM in EFC displacement assay, and 5500 nM in HTRF assay. | ||
| M14178 | p38 MAPK-IN-1 | p38 MAPK |
| p38 MAPK-IN-1 (Compound 4) is a novel potent and selective inhibitor of p38 MAPK with IC50 of 68 nM. p38 MAPK-IN-1 shows sustained levels, low clearance and good bioavailability. | ||
| M1675 | BIRB796 | p38 MAPK |
| Doramapimod | ||
| BIRB 796 (Doramapimod) is a protein kinase inhibitor of p38 MAPK with Kd of 100pM. | ||
| M1781 | Adezmapimod (SB203580) | p38 MAPK |
| RWJ 64809; PB 203580; Adezmapimod | ||
| Adezmapimod (SB203580) is a P38 MAPK inhibitor with an IC50 of 0.3-0.5 μM, which is 10 times less selective than SAPK3(106T) and SAPK4(106T), and inhibits PKB phosphorylation with an IC50 of 3-5 μM. | ||
| M2317 | VX-702 | p38 MAPK |
| VX-702 is a highly selective inhibitor of p38 MAPKα with IC50 of 4-20 nM. | ||
| M2318 | Ralimetinib dimesylate | p38 MAPK |
| LY2228820 dimesylate; LY2228820 2MsOH | ||
| Ralimetinib dimesylate (LY2228820 dimesylate) is a novel and potent inhibitor of p38 MAPK with IC50 of 7 nM. | ||
| M3011 | Skepinone-L | p38 MAPK |
| Skepinone L | ||
| Skepinone-L is a selective p38α-MAPK inhibitor with IC50 of 5 nM. | ||
| M3048 | TAK-715 | p38 MAPK |
| TAK-715 is a p38 MAPK inhibitor for p38α with IC50 of 7.1 nM, 28-fold more selective for p38α over p38β, no inhibition to p38γ/δ, JNK1, ERK1, IKKβ, MEKK1 or TAK1. | ||
| M3751 | Losmapimod | p38 MAPK |
| GW-856553X; GSK-AHAB; SB856553 | ||
| Losmapimod (GW856553) is a selective, potent, and orally active p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively. | ||
| M3890 | SU9516 | CDK |
| 666837-93-0 | ||
| SU9516 is a selective CDK2 inhibtor with IC50 of 22 nM which is less potent for CDK1/CDK4(IC50=40/200 nM) and has no inhibition on PKC, EGFR, p38MAPK etc. | ||
| M8991 | Dilmapimod | p38 MAPK |
| SB-681323; GW-681323 | ||
| Dilmapimod (also known as SB-681323 and GW-681323) is a p38 MAPK inhibitor that potentially suppresses inflammation in COPD. | ||
| M4166 | 1-Cinnamoyltrichilinin | Others |
| 1-Cinnamoyltrichilinin from Melia azedarach Causes Apoptosis through the p38 MAPK Pathway in HL-60 Human Leukemia Cells. | ||
| M4179 | Neochlorogenic-acid | NF-κB |
| trans-5-O-Caffeoylquinic acid | ||
| Neochlorogenic acid is a natural polyphenolic compound found in dried fruits and other plants. Neochlorogenic acid can inhibit the production of TNF-α and IL-1β. Neochlorogenic acid inhibited the expression of iNOS and COX-2 proteins. Neochlorogenic acid also inhibited the activation of phosphorylated NF-κB P65 and P38 MAPK. | ||
| M4415 | Sesamolin | p38 MAPK |
| Sesaminol can be isolated from Justicia Orbiculata and has antioxidant activity. Sesaminol inhibits lipid peroxidation and has neuroprotective effect. Sesaminol inhibits MAPK cascade by inhibiting phosphorylation of JNK, P38 MAPKs, and Caspase-3. | ||
| M4521 | Dehydrocorydaline | Bcl-2 |
| 13-Methylpalmatine | ||
| Dehydrocorydaline is an alkaloid, it can regulate protein expression of Bax, Bcl-2. Dehydrocorydaline elevates p38 MAPK activation. Dehydrocorydaline elevates p38 MAPK activation. Anti-inflammatory and anti-cancer activities. Dehydrocorydaline shows strong anti-malarial effects, and low cytotoxicity. | ||
| M5873 | Pexmetinib (ARRY-614) | p38 MAPK |
| ARRY-614 | ||
| Pexmetinib (ARRY-614) is a potent, orally bioavailable, dual p38 MAPK/Tie-2 inhibitor with IC50 of 4 nM/18 nM in a HEK-293 cell line. Phase 1. | ||
| M6146 | TA-02 | p38 MAPK |
| TA 02; TA02 | ||
| TA-02 is a p38 MAPK inhibitor with IC50 of 20 nM. TA-02 especially inhibits TGFBR-2. | ||
| M6581 | CGH 2466 dihydrochloride | Others |
| CGH 2466 dihydrochloride is a a 1, A 2B and A 3 antagonist and inhibitor of p38 MAPK and PDE4. | ||
| M6602 | Ciglitazone | PPAR |
| ADD-3878; U-63287 | ||
| Ciglitazone is an effective selective PPARγ agonist (EC50=3 μM). Ciglitazone inhibited the proliferation and differentiation of TH17 cells. Ciglitazone is an oral hypoglycemic agent that has been shown to be active in obese hyperglycemic animal models. Ciglitazone induces apoptosis in opossum renal epithelial cells and simultaneously activates nuclear translocation of P38 MAPK and apoptosis-inducing factor (AIF). | ||
| M6978 | ML3403 | p38 MAPK |
| ML 3403 | ||
| ML3403 is a potent p38 MAPK inhibitor with an IC50 of 0.38 μM. | ||
| M7249 | SB 203580 hydrochloride | p38 MAPK |
| Adezmapimod hydrochloride ; RWJ 64809 hydrochloride | ||
| SB 203580 hydrochloride is a selective inhibitor of p38 MAPK; water-soluble. | ||
| M7558 | SD-06 | p38 MAPK |
| SD-06 is a p38 MAP kinase inhibitor; inhibits p38α with an IC50 value of 170 nM and inhibits LPS-stimulated TNF-release in rats (83% inhibition at 1mg/kg, po). IC50 value: 170 nM Target: p38MAPK | ||
| M7582 | SB 239063 | p38 MAPK |
| SB 239063 is a potent and selective p38 MAPK inhibitor (IC50 = 44 nM for p38α). SB 239063 displays > 220-fold selectivity over ERK, JNK1 and other kinases; ~ 3-fold more selective than SB 203580. | ||
| M7630 | Butein | PDE |
| 2’,3,4,4’-tetrahydroxy Chalcone | ||
| Butein is a cAMP-specific PDE inhibitor with an IC50 of 10.4 μM for PDE4. Butein is a specific protein tyrosine kinase inhibitor with IC50s of 16 and 65 μM for EGFR and p60c-src in HepG2 cells. Butein sensitizes HeLa cells to Cisplatin through AKT and ERK/p38 MAPK pathways by targeting FoxO3a. Butein is a SIRT1 activator. | ||
| M8168 | sPLA2 inhibitor | Phospholipase |
| Secretory phospholipase A2 inhibitor blocks the activation of NF-κB, Akt, p38 MAPK and ERK pathways. | ||
| M9160 | BMS-582949 | p38 MAPK |
| PS540446; BMS582949 free base | ||
| BMS-582949 is a potent and selective P38 mitogen-activated protein kinase (P38 MAPK) inhibitor with IC50 of 13nM. | ||
| M9223 | R-268712 | TGF-beta/Smad |
| R-268712 is a potent and selective inhibitor of ALK5 with an IC50 of 2.5nM, an approximately 5000-fold more selectivity for ALK5 than p38 mitogen-activated protein kinase (MAPK). | ||
| M10551 | Gypenoside L | p38 MAPK |
| Gyp-L | ||
| Gypenoside L activates p38 and ERK MAPK pathways and NF-κB pathway to induce senescence, it is a saponin that can be found in Gynostemma pentaphyllum. | ||
| M10609 | Ergothioneine | Metabolite/Endogenous Metabolite |
| L-(+)-Ergothioneine | ||
| Ergothioneine is an imidazole-2-thione derivative of histidine betaine, generally considered as an antioxidant. Ergothioneine is a specific inhibitor of p38-MAPK and Akt, which plays a protective role in cell apoptosis induced by stress. Ergothioneine has antioxidant activity. | ||
| M13530 | Dehydrocorydaline chloride | Bcl-2 |
| 13-Methylpalmatine chloride | ||
| Dehydrocorydaline chloride (13-Methylpalmatine chloride) is an alkaloid that regulates protein expression of Bax, Bcl-2; activates caspase-7, caspase-8, and inactivates PARP. Dehydrocorydaline chloride elevates p38 MAPK activation. Dehydrocorydaline chloride has anti-inflammatory and anti-cancer activities. | ||
| M14174 | BMS-582949 hydrochloride | p38 MAPK |
| BMS-582949 hydrochloride is an orally active and highly selective p38α MAPK inhibitor, with an IC50 of 13 nM. BMS-582949 hydrochloride displays a significantly improved pharmacokinetic profile and is effective in inflammatory disease. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
